Applications of Ibuprofen Lysine in Industrial Manufacturing

Ibuprofen Lysine serves as a critical raw material across multiple regulated industries, notably in the pharmaceutical sector, where its solubility and bioavailability support the design and scale-up of specific dosage forms. Our facility supplies high-purity grades intended for downstream use in various finished products, consistently meeting global quality and compliance benchmarks.

1. Pediatric Oral Suspension Formulation

Pediatric manufacturers select this ingredient due to its high aqueous solubility, which allows precise dosing and easier formulation of liquid suspensions for children. The improved taste-masking versus standard Ibuprofen salts facilitates direct suspension blending, streamlining batch production and reducing flavor correction steps. Aqueous compatibility supports both continuous and batch manufacturing lines, with suspended microfine particles remaining stable through the shelf life, as verified by stability studies. Formulators achieve uniform active dispersion with low sedimentation risk during filling and transport stages.

Industry compliance standards

• U.S. FDA 21 CFR Part 210/211 (cGMP for Finished Pharmaceuticals)
• USP Monograph for Ibuprofen Lysine
• Ph. Eur. Ibuprofen Lysine standard
• ICH Q6A/Q3C impurity and specification guidelines

Typical usage ratio

• 2.0 – 4.0% w/v of total suspension, titrated to deliver 100 mg–200 mg per 5 mL dose, adjusted by age bracket and regional labeling limits

Downstream process integration

• Dispersed into deionized water phase during main mixing, following pre-wet with wetting agents to minimize agglomeration
• Flavorants and preservatives added post-dispersion, followed by pH adjustment and final milling/homogenization

Final product types

• Pediatric analgesic/antipyretic oral suspensions
• Ready-to-dispense children’s syrup
• Hospital bulk oral analgesic liquids for pediatric use
• Pharmacy-compounded pediatric suspensions

2. Fast-Acting Tablet Manufacturing

Production facilities specializing in fast-acting pain relief tablets prefer ibuprofen lysine for its improved dissolution kinetics compared to the standard acid form. Its salt structure accelerates disintegration, reducing onset times and supporting claims of rapid relief in patient leaflets. Consistent granulation and direct compression performance decreases blending time while maintaining uniformity. Automated coating systems further benefit from the salt's high flowability and reduced electrostatic charging, minimizing dust during handling. Quality teams verify content uniformity and dissolution, referencing real-time process monitoring data from critical control points.

Industry compliance standards

• Ph. Eur. 2.9.1 and USP General Chapter <904> on dissolution and content uniformity
• GMP ICH Q7 for API manufacturing
• FDA DMF Type II referencing Ibuprofen Lysine
• CPMP/QWP/155/96 for oral solid dosage forms

Typical usage ratio

• 200 mg – 400 mg per tablet core (20% – 45% w/w of total tablet mass), adjusted for fast-release design and regional maximum daily dose limits

Downstream process integration

• Introduced at dry blending stage with disintegrants and flow aids
• Granulated with low moisture process or directly compressed, depending on target dissolution profile
• Optional film coating step utilizes aqueous or solvent polymers, as validated in process qualification runs

Final product types

• Fast-acting analgesic tablets
• Film-coated pain relief tablets
• OTC and prescription rapid-release oral solids
• Day/night acute analgesic combination capsules

3. Intravenous Infusion Solution Preparation

Parenteral solution manufacturers use this salt form to produce concentrated ibuprofen infusions due to its excellent aqueous solubility and stability at hospital-compatible pH ranges. Lowered risk of precipitation and particulate contamination supports strict aseptic processes during filling and terminal sterilization. The material participates directly in sterile compounding suites, where closed-system transfer devices and multi-stage filtration eliminate pyrogen and bioburden risks. Pharmacy departments can reconstitute master vials without further solubilizers, ensuring reliable delivery at the point of care. Stability and isotonicity studies confirm appropriate shelf-life and compatibility with IV bags and ancillary infusion sets.

Industry compliance standards

• USP <788> Particulate Matter in Injections
• FDA 21 CFR Part 610 Sterility Requirements
• ICH Q1A (R2) stability guidelines for parenterals
• European Pharmacopoeia Monograph on Ibuprofen Lysinate Injection

Typical usage ratio

• 10 mg/mL – 40 mg/mL, titrated to meet common adult and pediatric single-dose infusion requirements

Downstream process integration

• Dissolved into Water for Injection (WFI) under controlled pH and temperature conditions
• Sterile filtration (0.22 μm) before aseptic vial or ampoule filling
• Terminal sterilization, as validated by bacterial endotoxin testing per local pharmacopoeia

Final product types

• Hospital-ready IV ibuprofen solutions
• Multi-dose parenteral analgesic vials
• Single-use infusible ampoules
• Custom IV admixture compounded bags for surgery and PICU use

4. Granular Sachet and Powder Preparations

Sachet and powder stick pack manufacturers select this salt form when designing high-load, rapidly reconstituting formats for adults and adolescents. The improved palatability and fast dissolution characteristics reduce the need for additional solubilizers, while robust particle size control improves long-term blend uniformity and packaging fill accuracy. Facilities automate blending and sachet filling on high-speed lines, using in-process NIR to monitor density changes throughout shifts. Consistent flowability and minimal hygroscopicity support extended storage and transport in diverse climates. Downstream QC teams perform accelerated stability and impurity profiling in line with regulatory standards for reconstitutable oral powders.

Industry compliance standards

• EU Directive 2001/83/EC for oral solid medicines
• Ph. Eur. and JP compendial tests for oral powders
• ICH Q3B Residual Solvents (where flavorants are used)
• ISO 22000:2018 for lines shared with food-grade actives

Typical usage ratio

• 200 mg – 600 mg per sachet or stick pack, 30% – 65% w/w of formula, matched to single-dose or multi-dose units within national labeling rules

Downstream process integration

• Pre-blended with excipient base prior to introduction of flavor and anticaking agents
• Batch monitored for particle size and moisture prior to automated packaging
• Final in-sachet blending step ensures dose uniformity across production lots

Final product types

• Instant reconstitutable analgesic powders
• Adult and adolescent pain relief sachets
• Travel-friendly stick packs for acute pain management
• Multi-dose bulk oral powder jars for clinical use